Cover Image
市場調查報告書

Adalimumab的南美市場:產業分析、規模、佔有率、成長率、趨勢、預測 (類風濕性關節炎、乾癬、克隆氏症、潰瘍性大腸炎、其他) 2015年∼2023年

LATAM Adalimumab Market (Application-Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, and Others) - Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 352928
出版日期 內容資訊 英文 61 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Adalimumab的南美市場:產業分析、規模、佔有率、成長率、趨勢、預測 (類風濕性關節炎、乾癬、克隆氏症、潰瘍性大腸炎、其他) 2015年∼2023年 LATAM Adalimumab Market (Application-Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, and Others) - Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
出版日期: 2016年01月28日 內容資訊: 英文 61 Pages
簡介

本報告提供南美的Adalimumab市場相關調查分析,各應用以及各國,數量、收益的實際成果資料與預測,推動因素、阻礙因素,主要企業等系統性資訊。

第1章 序文

第2章 摘要整理

第3章 南美的Adalimumab市場:產業分析

  • 簡介
  • 市場成長的促進要素
  • 市場阻礙成長要素
  • 市場機會
  • 市場魅力度分析
  • 開發平台分析

第4章 南美的Adalimumab市場區隔:各應用領域

  • 簡介
  • 南美的Adalimumab市場收益:各應用領域
  • 類風濕性關節炎
  • 乾癬
  • 克隆氏症
  • 潰瘍性大腸炎
  • 其他

第5章 南美的Adalimumab市場區隔:各國

  • 簡介
  • 南美的Adalimumab市場收益:各國
  • 巴西
  • 墨西哥
  • 阿根廷
  • 哥倫比亞
  • 其他南美國家

第6章 建議

第7章 企業簡介

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim GmbH
  • Eisai
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.

圖表

目錄

This report on LATAM Adalimumab market analyzes the current and future prospects of the adalimumab sales pertaining to Latin American countries. The stakeholders of this report include companies engaged in production and commercialization of adalimumab biosimilars across the globe. This report encompasses an elaborate executive summary, with a market snapshot that provides overall information of major market segments and sub-segments included in the study scope. This section also provides the overall information and data analysis of the LATAM Adalimumab market with respect to the leading market segments based on, application and major Latin American countries.

The LATAM Adalimumab market has been segmented on the basis of application, and Latin American countries. The application segment has been further segmented into rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis and others. The LATAM adalimumab country segment has been further categorized into Brazil, Mexico, Argentina, Colombia and Rest of LATAM. The market for each of these segment has been analyzed on the basis of adalimumab prescription for various disorders and regulatory scenario with respect to biologic drugs in respective countries. Market revenue in terms of US$ Mn for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all the segments, considering 2014 as the base year.

The market overview section of this report explores market dynamics such as drivers, restraints, and opportunities that have predominant impact on the LATAM adalimumab market presently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to elucidate the intensity of competition in the market in different LATAM countries. Furthermore, pipeline analysis of the adalimumab biosimilar molecules in Phase III stage have been provided in market overview section. The market estimations for pipeline molecules are provided assuming the positive entry of these molecules in the market which will have an impact on the sustainability of the companies operating in this market. All these factors would help the market players to take strategic decisions in order to strengthen their positions and expand their shares in the LATAM market.

The LATAM adalimumab analysis with respect to major LATAM countries provides the landscape for the production and marketing of adalimumab biosimilars with the introduction of favorable reimbursement policies, research expertise which paves a path for the local and foreign investments in these countries. The report also profiles major players in the adalimumab market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the major players profiled in this report include AbbVie, Inc., Amgen, Inc., Mylan N.V., Novartis AG, Pfizer, Inc. and others.

The LATAM Adalimumab market is segmented into the following categories:

LATAM Adalimumab Market, by Application

  • Rheumatoid Arthritis
  • Psoriasis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Others

LATAM Adalimumab Market, by Country

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM

Table of Contents

1. Preface

2. Executive Summary

  • 2.1. LATAM Adalimumab: Market Snapshot
  • 2.2. Comparative Analysis: LATAM Adalimumab Market, by Country, 2014 & 2023 (Value %)
  • 2.3. LATAM Adalimumab Market Revenue, by Application, 2014 (US$ Mn)

3. Industry Analysis: LATAM Adalimumab Market

  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Driver 1: Favorable Local Regulations
    • 3.2.2. Driver 2: Expertise in Biologic Product Research To Support Local And Foreign Investments
  • 3.3. Market Restraints
    • 3.3.1. Restraint 1: High Cost of R&D and Clinical trials
    • 3.3.2. Restraint 2: Lack of reimbursement for biosimilars resulting in high out-of-pocket costs
  • 3.4. Market Opportunities
    • 3.4.1. Opportunity 1: LATAM, an attractive base for the biosimilar developers for their product expansion
  • 3.5. Market Attractiveness Analysis - LATAM Adalimumab Market, by Country (2014) (value %)
  • 3.6. Pipeline Analysis: LATAM Adalimumab Market

4. LATAM Adalimumab Market Segmentation - by Application

  • 4.1. Introduction
  • 4.2. LATAM Adalimumab Market Revenue, by Application 2013-2023 (US$ Mn)
  • 4.3. LATAM Adalimumab Market Revenue for Rheumatoid Arthritis, 2013-2023, (US$ Mn)
  • 4.4. LATAM Adalimumab Market Revenue for Psoriasis, 2013-2023, (US$ Mn)
  • 4.5. LATAM Adalimumab Market Revenue for Crohn's Disease, 2013-2023, (US$ Mn)
  • 4.6. LATAM Adalimumab Market Revenue for Ulcerative Colitis, 2013-2023, (US$ Mn)
  • 4.7. LATAM Adalimumab Market Revenue for Others, 2013-2023, (US$ Mn)

5. LATAM Adalimumab Market Segmentation - by Country

  • 5.1. Introduction
  • 5.2. LATAM Adalimumab Market Revenue, by Country, 2013-2023 (US$ Mn)
  • 5.3. Brazil Adalimumab Market Revenue, 2013-2023 (US$ Mn)
  • 5.4. Mexico Adalimumab Market Revenue, 2013-2023 (US$ Mn)
  • 5.5. Argentina Adalimumab Market Revenue, 2013-2023 (US$ Mn)
  • 5.6. Colombia Adalimumab Market Revenue, 2013-2023 (US$ Mn)
  • 5.7. Rest of LATAM Adalimumab Market Revenue, 2013-2023 (US$ Mn)

6. Recommendations

7. Company Profiles

  • 7.1. AbbVie, Inc.
  • 7.2. Amgen, Inc.
  • 7.3. Boehringer Ingelheim GmbH
  • 7.4. Eisai Co., Ltd.
  • 7.5. Mylan N.V.
  • 7.6. Novartis AG
  • 7.7. Pfizer, Inc.
Back to Top